Sab, of course they are going to present at JPM: they have great molecules and great data even if they have made some regulatory stumbles. They will work through it. They will be far from the most imcompetent company at JPM and are in the top 5% with respect to quality of therapeutics. People don't stop showing up just because they made mistakes. Conference halls would be empty everywhere if that were the case.
Let the process play all the way out. And let's see what CM has to say next Tuesday about moving both 2-73 and 3-71 to commercialization. We get up off the floor, dust ourselves off, and get back in there. That is what we all do.
Market Data 
Markets 
AI
